<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164175</url>
  </required_header>
  <id_info>
    <org_study_id>HRG1301.000-M</org_study_id>
    <nct_id>NCT02164175</nct_id>
  </id_info>
  <brief_title>Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis</brief_title>
  <official_title>Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemosphere, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hemosphere, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving
      Hemodialysis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection including medical history, operative procedure data, and follow-up data every
      six months while using the HeRO Graft for dialysis, including:

        -  Post-operative complications for HeRO Graft implantation

        -  Length of time between insertion and use of HeRO Graft

        -  Incidence of thrombosis

        -  Hospitalizations

        -  Incidence of infections and other adverse event occurrence

        -  Mortality

        -  Hemoglobin

        -  Kt/V

        -  pre-dialysis blood pressure

        -  post-dialysis blood pressure

        -  blood flow rate and

        -  dialysis flow rate
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the death rate of participants using the HeRO Graft is less than the death rate of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adequacy of dialysis (Kt/V)</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the adequacy of dialysis of participants using the HeRO Graft is better than the adequacy of dialysis of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the infection rate of participants using the HeRO Graft is less than the infection rate of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization rate</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the hospitalization rate of participants using the HeRO Graft is less than that of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patency rate</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the patency rate of participants using the HeRO Graft is less than that of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Intervention rate</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the intervention rate of participants using the HeRO Graft is less than that of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the number of adverse events of participants using the HeRO Graft is less than that of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Every six months post-implant until death or no longer using HeRO Graft for dialysis, up to five years</time_frame>
    <description>To evaluate if the blood pressure of participants using the HeRO Graft is less than that of patients who do not receive the HeRO Graft and continue to use a tunneled dialysis catheter for dialysis.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>HeRO Graft</arm_group_label>
    <description>End stage renal disease patients who receive HeRO Graft implant for dialysis access</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeRO Graft implant for dialysis access</intervention_name>
    <description>End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access</description>
    <arm_group_label>HeRO Graft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients eligible for HeRO Graft for dialysis access
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients eligible for HeRO Graft for dialysis access

          -  Age greater than 18 years old

          -  Able to give informed consent

        Exclusion Criteria:

          -  Subjects with any kind of disorder that compromises the ability of the subject to give
             informed consent and/or to comply with the study procedures;

          -  Any medical condition that in the opinion of the investigator may pose a safety risk
             to a subject in the study or which may interfere with study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Lawson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Lawson, MD</last_name>
      <phone>919-681-2533</phone>
      <email>jeffrey.lawson@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dana Giangiacomo, RN</last_name>
      <phone>919-681-1092</phone>
      <email>dana.giangiacomo@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen E Hohmann, MD</last_name>
      <phone>214-821-9600</phone>
      <email>drhohmann@me.com</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Fisher, RN</last_name>
      <phone>214-820-7221</phone>
      <email>tammyfi@BaylorHealth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group Sentara Vascular Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel N Steerman, MD, RPVI</last_name>
      <phone>757-470-5570</phone>
      <email>snsteerm@sentara.com</email>
    </contact>
    <contact_backup>
      <last_name>Jan L Devlin, RN</last_name>
      <phone>757-388-5629</phone>
      <email>JLDEVLIN@sentara.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.herograft.com</url>
    <description>HeRO Graft website</description>
  </link>
  <reference>
    <citation>Gage SM, Katzman HE, Ross JR, Hohmann SE, Sharpe CA, Butterly DW, Lawson JH. Multi-center experience of 164 consecutive Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment. Eur J Vasc Endovasc Surg. 2012 Jul;44(1):93-9. doi: 10.1016/j.ejvs.2012.04.011. Epub 2012 May 12.</citation>
    <PMID>22580402</PMID>
  </reference>
  <reference>
    <citation>Katzman HE, McLafferty RB, Ross JR, Glickman MH, Peden EK, Lawson JH. Initial experience and outcome of a new hemodialysis access device for catheter-dependent patients. J Vasc Surg. 2009 Sep;50(3):600-7, 607.e1. doi: 10.1016/j.jvs.2009.04.014. Epub 2009 Jul 22.</citation>
    <PMID>19628360</PMID>
  </reference>
  <reference>
    <citation>Nassar GM, Glickman MH, McLafferty RB, Croston JK, Zarge JI, Katzman HE, Peden EK, Lawson JH, Martinez JM, Thackeray L. A comparison between the HeRO graft and conventional arteriovenous grafts in hemodialysis patients. Semin Dial. 2014 May-Jun;27(3):310-8. doi: 10.1111/sdi.12173. Epub 2014 Jan 15.</citation>
    <PMID>24428351</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>December 23, 2015</last_update_submitted>
  <last_update_submitted_qc>December 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeRO Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

